Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

38
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
38
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

40
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
40

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Heart Failure in Adult Congenital Heart Disease.

Methodist DeBakey cardiovascular journal·2026
Same author

When does additional information improve accuracy of RNA secondary structure prediction?

bioRxiv : the preprint server for biology·2026
Same author

Long-Term HM3 Outcomes: Is Age the Signal or the Surrogate?

JACC. Heart failure·2026
Same author

<i>In vitro</i> and <i>in vivo</i> activity of omadacycline against <i>Mycobacterium tuberculosis</i>.

Frontiers in microbiology·2026
Same author

Marine plastic pollution undermines the livelihoods and income of fishing communities in Viet Nam.

Communications earth & environment·2026
Same author

Artificial intelligence for right ventricular assessment: current evidence and future directions.

Current opinion in cardiology·2026

相关实验视频

Updated: Sep 17, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K

等候名单死亡率的差异:临时和持久的循环支持器件.

Mahwash Kassi1, Salma Zook1, Duc Nguyen2

  • 1Department of Cardiology, Houston Methodist Hospital - DeBakey Heart and Vascular Center, Houston, TX.

JHLT open
|July 3, 2025
PubMed
概括
此摘要是机器生成的。

耐用左心室辅助器件 (LVADs) 在心脏移植患者中显示出比暂时的机械循环支持更好的结果. 该HeartMate 3 LVAD显示,等候名单死亡率和退出等候名单的风险最低.

关键词:
心脏移植心脏移植手术机械循环支持 机械循环支持倾向性得分匹配 - 匹配的倾向性得分在UNOS分配系统的分配系统中,等待名单死亡率等待名单死亡率

更多相关视频

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.5K

相关实验视频

Last Updated: Sep 17, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.7K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.5K

科学领域:

  • 心脏病学 心脏病学
  • 移植医学 移植医学
  • 医疗器械 医疗器械

背景情况:

  • 2018年联合器官共享网络 (UNOS) 分配系统的变化影响了耐用左心室辅助器件 (LVAD) 和临时机械循环支持 (MCS) 的使用,作为通往心脏移植的桥梁.
  • 这种转变需要对这两种支持策略之间的患者结果进行比较分析.

研究的目的:

  • 为了比较耐用LVAD和临时MCS支持的患者在一年内等候名单死亡率和删除事件的复合结果.
  • 在更新的器官分配政策的背景下,评估不同机械循环支持装置的有效性.

主要方法:

  • 一项队列研究包括2018年10月至2021年10月期间在机械循环支持上进行心脏移植的成年患者.
  • 排除标准包括使用右心室装置,双心室装置,全人工心脏和体外膜氧化器的患者.
  • 倾向性得分匹配用于比较持久的LVAD和临时的MCS组之间的结果,使用Kaplan-Meier曲线和Cox回归的生存分析.

主要成果:

  • 该研究分析了4,569名患者 (1,877名临时MCS,2,692名持久LVAD),在倾向性得分匹配后包括了660名患者.
  • 复合事件发生率在持久性LVAD组 (15.9%) 与临时性MCS组 (35.2%) 相比显著较低 (p < 0.001).
  • 暂时的MCS与显著更高的不良结果危险比率 (HR) 相关 (HR 3.37,p < 0.001),其中HeartMate 3 (HM3) 设备显示出最好的结果.

结论:

  • 在与倾向分数相匹配的分析中,持久的机械循环支持与等待心脏移植的患者的临时机械循环支持相比,显示出更好的结果.
  • 该HeartMate 3设备与组合不良结果的风险最低相关,突出显示其在该患者群体中的有效性.